Fouad Amr A, Qutub Hatem O, Al Rashed Abdullatif S, Al-Melhim Walid N
Biomedical Sciences Department, Division of Pharmacology, College of Medicine, King Faisal University, Al-Ahsa, 31982, Saudi Arabia.
Internal Medicine Department, College of Medicine, University of Dammam, Dammam, Saudi Arabia.
Environ Toxicol Pharmacol. 2017 Dec;56:10-14. doi: 10.1016/j.etap.2017.08.021. Epub 2017 Aug 26.
The possible anticancer effect of carnosine versus doxorubicin was investigated against hepatocellular carcinoma (HCC) induced by trichloroacetic acid (TCA) (500mg/kg/day, p.o., for 5days) in rats. Following induction of HCC, rats treated with either carnosine (10mg/kg/day, i.p.), or doxorubicin (2.5mg/kg, i.p., once weekly), for 2 weeks. Carnosine significantly decreased serum alanine aminotransferase, and hepatic lipid peroxidation, nitric oxide, tumor necrosis factor-α, and nuclear factor-κB p65 unit, and significantly increased liver total antioxidant status in TCA-challenged rats. The effects of doxorubicin on oxidative, nitrative, and inflammatory biomarkers were less significant than carnosine. However, both carnosine and doxorubicin significantly induced liver tissue apoptotic biomarkers, Bax, cytosolic cytochrome C, and caspase-3, in a comparable manner. Additionally, carnosine and doxorubicin reduced the histopathological dysplastic changes, and alpha-fetoprotein expression in liver of rats with HCC. It was concluded that carnosine significantly protected against TCA-induced liver carcinogenesis in rats, through its antioxidant, antinitrative, and anti-inflammatory effects, and induction of apoptosis.